• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Securities Act of 1933

Securities Act of 1933

  1. All
  2. 3rd Party
  3. Investing
  1. Carmila launches a c. Euro 557 million capital increase in order to pursue its development plan

    Carmila launches a c. Euro 557 million capital increase in order to pursue its development plan

  2. STORE Capital Announces Investment from Berkshire Hathaway

    STORE Capital Announces Investment from Berkshire Hathaway

  3. Korian Launches an Offering of Unsubordinated Undated Bonds Convertible into New Shares and/or Exchangeable for Existing Shares (ODIRNANE) for an Amount of Approximately € 200 Million

    Korian Launches an Offering of Unsubordinated Undated Bonds Convertible into New Shares and/or Exchangeable for Existing Shares (ODIRNANE) for an Amount of Approximately € 200 Million

  4. Korian Announces Its Final Terms of the Unsubordinated Undated Bonds Convertible into New Shares and/or Exchangeable for Existing Shares (ODIRNANE) fOr an Amount of Approximately € 240 Million

    Korian Announces Its Final Terms of the Unsubordinated Undated Bonds Convertible into New Shares and/or Exchangeable for Existing Shares (ODIRNANE) fOr an Amount of Approximately € 240 Million

  5. Belden Announces €400 Million Private Offering of Senior Subordinated Notes

    Belden Announces €400 Million Private Offering of Senior Subordinated Notes

  6. Belden Announces Pricing of Upsized €450 Million Private Offering of 3.375% Senior Subordinated Notes

    Belden Announces Pricing of Upsized €450 Million Private Offering of 3.375% Senior Subordinated Notes

  7. The Royal Bank of Scotland plc - Stabilisation Notice

    The Royal Bank of Scotland plc - Stabilisation Notice

  8. Bank of the Ozarks Completes Internal Reorganization

    Bank of the Ozarks Completes Internal Reorganization

  9. The Royal Bank of Scotland plc - Stabilisation Notice

    The Royal Bank of Scotland plc - Stabilisation Notice

  10. Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

    Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

12345

©2017 Morningstar Advisor. All right reserved.